Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules

Identification of potent anticancer agents with high selectivity and low toxicity remains on the way to human health. Pyridazine featuring advantageous physicochemical properties and antitumor potential usually is regarded as a central core in numerous anticancer derivatives. There are several approved pyridazine-based drugs in the market and analogues currently going through different clinical phases or registration statuses, suggesting pyridazine as a promising drug-like scaffold. The current review is intended to provide a comprehensive and updated overview of pyridazine derivatives as potential anticancer agents. In particular, we focused on their structure-activity relationship (SAR) studies, design strategies, binding modes and biological activities in the hope of offering novel insights for further rational design of more active and less toxic anticancer drugs. (c) 2020 Elsevier Masson SAS. All rights reserved.

Automated summary

Identification of potent anticancer agents with high selectivity and low toxicity remains an ongoing challenge. Pyridazine, known for its advantageous physicochemical properties and antitumor potential, is considered a promising drug-like scaffold. This review focuses on the structure-activity relationship studies and design strategies of pyridazine derivatives as potential anticancer agents.